Adam Samuel Abdur-Rahim Sperling, MD
Hematology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Offices
- 3
Offices
3 locations · Stanford Health Care · Dana-Farber Cancer Institute, Inc. · Brigham and Womens Physicians Organization Inc
Looking this up.
Hospitals listed: Brigham and Women'S Hospital · Dana-Farber Cancer Institute. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sperling’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Brigham and Women'S HospitalBoston, MAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Mass General Brigham, which runs 15 hospitals in 2 statesHome of Dana-Farber/Harvard Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.711, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.596, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.505, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.51, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.6 to 0.9) · 2,432 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Brigham and Women'S Hospital
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.711 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.596 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.505 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.51 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 0.9) · 2,432 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.69 (0.12 to 1.26) · 6,008 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.74 to 1.01) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 158.29 (133.21 to 183.36) · 505 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.2 · 365 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 155 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.1 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.7 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.1 · 697 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.5 · 456 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 6,699 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0.01 to 0.29) · 21,284 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.13 to 0.42) · 24,178 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.49 (3.47 to 5.51) · 9,415 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.37 (1.52 to 3.21) · 5,676 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.05 (1.23 to 2.88) · 8,589 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.32 (5.06 to 9.58) · 5,122 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.49 (3.06 to 5.92) · 5,826 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.31 (0.19 to 2.43) · 2,520 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.34 (0.05 to 0.63) · 21,256 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 384 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0.332 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.684 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.9 · 576 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 1,117 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 30 · 580 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 24.9 · 1,164 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 16.7 · 758 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 721 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.6 (3 to 7.2) · 175 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 7.5 (5.3 to 10.9) · 175 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.6 · 371 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 168 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.5 (9.5 to 14) · 5,029 cases | No different | Jan 2022 – Dec 2024 |
What patients said (666 patients answered, 23% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 67% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 81% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$16,188
Medicare paid this office $16,188 for 99 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 37 | $6,034 | $110 |
| Return visit (30+ min) | 36 | $2,928 | $75 |
| New patient visit (60+ min) | 12 | $1,821 | $152 |
Who their Medicare patients are
99 Original Medicare patients in 2024. Average age 73 · Women 46% · Also on Medicaid 17% · Health risk score 2.30. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: High blood pressure 63% · Chronic kidney disease 38% · Coronary heart disease 33% · Depression 28% · Diabetes 27% · Cancer 25% · Atrial fibrillation 24% · Heart failure 23% · COPD 15% · Stroke 14%.
The office billed $96,764, Medicare allowed $21,447 and paid $16,188; for 175 services of 10 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 99 | 175 | 73 | 2.30 | $96,764 | $16,188 |
| 2023 | 95 | 179 | 71 | 2.38 | $103,559 | $17,549 |
| 2022 | 93 | 230 | 69 | 2.86 | $120,388 | $22,393 |
| 2021 | 71 | 210 | 74 | 2.03 | $101,598 | $21,999 |
| 2020 | 55 | 154 | 72 | 2.53 | $51,793 | $12,687 |
| 2019 | 65 | 180 | 73 | 3.15 | $52,434 | $16,208 |
| 2018 | 13 | 22 | 73 | 0.80 | $4,270 | $2,191 |
| 2017 | 28 | 65 | 71 | 1.52 | $4,746 | $1,833 |
| 2016 | 48 | 75 | 75 | 1.26 | $4,950 | $3,018 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Long return visit (40+ min) | 47 | $9,165 | $117 |
| New patient visit (60+ min) | 15 | $2,225 | $148 |
| Return visit (30+ min) | 20 | $1,736 | $79 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,005 | $63 |
2022: 5 services
| Long return visit (40+ min) | 46 | $8,823 | $119 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $3,620 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $2,727 | $151 |
| New patient visit (60+ min) | 15 | $2,376 | $158 |
| Return visit (30+ min) | 19 | $1,612 | $77 |
2021: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $7,710 | $90 |
| Long return visit (40+ min) | 36 | $7,202 | $126 |
| New patient visit (60+ min) | 15 | $2,429 | $162 |
| Return visit (30+ min) | 22 | $2,400 | $77 |
2020: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $4,790 | $87 |
| Return visit (30+ min) | 22 | $3,355 | $63 |
| New patient visit (60+ min) | 17 | $2,419 | $142 |
2019: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $6,664 | $88 |
| Return visit (30+ min) | 22 | $3,842 | $67 |
| New patient visit (60+ min) | 21 | $3,073 | $146 |
2018: 1 service
| New patient visit (60+ min) | 11 | $1,407 | $128 |
2017: 1 service
| Short return visit (20+ min) | 28 | $1,422 | $51 |
2016: 1 service
| Short return visit (20+ min) | 46 | $2,617 | $55 |
Drugs they prescribed that Part D paid
$500,672
Pharmacies billed $500,672 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
68 generic and 28 brand-name prescriptions · $500,672 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Revlimid | 11 | $270,684 | $16,918 |
Year by year
| 2024 | 96 | 28 | None | 29% | $500,672 |
| 2023 | 67 | 19 | None | None | $262,586 |
| 2022 | 91 | 19 | None | None | $681,657 |
| 2021 | 90 | 22 | None | 41% | $649,826 |
| 2020 | 118 | 27 | None | 52% | $821,640 |
| 2019 | 114 | 14 | None | 33% | $357,066 |
| 2018 | 16 | None | 0% (0) | None | $445 |
| 2017 | 19 | 19 | None | None | $448 |
| 2016 | 26 | 19 | 0% (0) | None | $264 |
| 2015 | 65 | 17 | None | None | $2,729 |
| 2014 | 104 | 21 | None | 24% | $24,507 |
| 2013 | 46 | 19 | None | None | $2,275 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Revlimid | 12 | $220,472 | $18,373 |
2022: 3 drugs
| Revlimid | 23 | $431,980 | $18,782 |
| Acyclovir | 18 | $472 | $26 |
| Sulfamethoxazole-Trimethoprim | 11 | $112 | $10 |
2021: 2 drugs
| Revlimid | 29 | $514,558 | $17,743 |
| Acyclovir | 12 | $304 | $25 |
2020: 5 drugs
| Revlimid | 33 | $521,756 | $15,811 |
| Pomalyst | 18 | $298,437 | $16,580 |
| Colestipol | 12 | $786 | $65 |
| Acyclovir | 21 | $227 | $11 |
| Gabapentin | 11 | $184 | $17 |
2019: 2 drugs
| Revlimid | 23 | $349,776 | $15,208 |
| Valacyclovir | 13 | $251 | $19 |
2013: 1 drug
| Hydrochlorothiazide | 11 | $69 | $6 |
Money from drug and device companies
$174 in 2024
| 2024 | 1 | 1 | None | $174 |
| 2022 | 1 | 3 | None | $1,824 |
| 2021 | 1 | 1 | $1,000 | $1,000 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | Abecma | $174 | 1 payment
|
See the published payment
| E.R. Squibb & Sons L.L.C. | Meals · 2024-06-27 | Abecma | $174 |
See earlier years (2022, 2021)
2022: $1,824
| F. Hoffmann-La Roche AG | None | $1,824 | 3 payments
|
2021: $1,000
| Adaptive Biotechnologies | Clonoseq | $1,000 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharmaceuticals Corporation · Phase I, Open Label, Study of B-Cell Maturation Antigen (Bcma)-Directed Car-T Cells in Adult Patients With Relapsed and/Or Refractory Multiple Myeloma · 2022 | Their institution | $1,080,173 |
| Novartis Pharmaceuticals Corporation · Phase I, Open Label, Study of B-Cell Maturation Antigen (Bcma)-Directed Car-T Cells in Adult Patients With Relapsed and/Or Refractory Multiple Myeloma · 2025 | Their institution | $871,396 |
| Novartis Pharmaceuticals Corporation · Phase I, Open Label, Study of B-Cell Maturation Antigen (Bcma)-Directed Car-T Cells in Adult Patients With Relapsed and/Or Refractory Multiple Myeloma · 2021 | Their institution | $781,629 |
| Novartis Pharmaceuticals Corporation · Phase I, Open Label, Study of B-Cell Maturation Antigen (Bcma)-Directed Car-T Cells in Adult Patients With Relapsed and/Or Refractory Multiple Myeloma · 2023 | Their institution | $753,187 |
| Novartis Pharmaceuticals Corporation · Phase I, Open Label, Study of B-Cell Maturation Antigen (Bcma)-Directed Car-T Cells in Adult Patients With Relapsed and/Or Refractory Multiple Myeloma · 2024 | Their institution | $238,968 |
| Novartis Pharmaceuticals Corporation · Phase II, Open Label, Study of Phe885, A B-Cell Maturation Antigen (Bcma)-Directed Car-T Cells in Adult Patients With Relapsed and Refractory Multiple Myeloma · 2023 | Their institution | $129,868 |
| Novartis Pharmaceuticals Corporation · Phase I, Open Label, Study of B-Cell Maturation Antigen (Bcma)-Directed Car-T Cells in Adult Patients With Relapsed and/Or Refractory Multiple Myeloma · 2020 | Their institution | $99,377 |
| Novartis Pharmaceuticals Corporation · Long Term Follow Up of Patients Exposed To Lentiviral Based Cd19 Directed Car T Cell Therapy · 2024 | Their institution | $78,989 |
| Novartis Pharmaceuticals Corporation · Long Term Follow Up of Patients Exposed To Lentiviral Based Cd19 Directed Car T Cell Therapy · 2025 | Their institution | $46,681 |
| Novartis Pharmaceuticals Corporation · Phase II, Open Label, Study of Phe885, A B-Cell Maturation Antigen (Bcma)-Directed Car-T Cells in Adult Patients With Relapsed and Refractory Multiple Myeloma · 2024 | Their institution | $34,103 |
| Celgene Corporation · Phiib Ide-Cel Multi-Cohort Mm (1l, 2l, 4l+) Karmma-2 (Bb2121-Mm-002) - A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Evaluate the Efficacy and Safety of Bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clin · 2023 | Their institution | $7,886 |
| Celgene Corporation · A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Evaluate the Efficacy and Safety of Bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clinical High-Risk Multiple Myeloma. (Karmma-2) · 2025 | Their institution | $3,357 |
| Novartis Pharmaceuticals Corporation · Phase II, Open Label, Study of Phe885, A B-Cell Maturation Antigen (Bcma)-Directed Car-T Cells in Adult Patients With Relapsed and Refractory Multiple Myeloma · 2025 | Their institution | $2,910 |
| Novartis Pharmaceuticals Corporation · Cadpt07a12101 · 2023 | This clinician | $609 |
| Novartis Pharmaceuticals Corporation · Cphe885b12201 · 2024 | This clinician | $487 |
| Novartis Pharmaceuticals Corporation · Phase II, Open Label, Study of Phe885, A B-Cell Maturation Antigen (Bcma)-Directed Car-T Cells in Adult Patients With Relapsed and Refractory Multiple Myeloma · 2022 | Their institution | $211 |
Professional record
- NPI
- 1023303161
- Licence
- MA 247520, MA 254762
- Group
- Stanford Health Care · Dana-Farber Cancer Institute, Inc. · Brigham and Womens Physicians Organization Inc
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X); Internal medicine (207R00000X); Medical oncology (207RX0202X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2011-06-16
- NPI last updated
- 2026-04-15
- NPI record certified
- 2026-04-15
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 75 Francis St, Boston, MA, 02115